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Abstract
Background: This study assessed whether the number of comorbid conditions unrelated to diabetes was associated with a
delay in therapeutic progression of diabetes treatment in Australian veterans.
Methodology/Principal Findings: A retrospective cohort study was undertaken using data from the Australian Department
of Veterans’ Affairs (DVA) claims database between July 2000 and June 2008. The study included new users of metformin or
sulfonylurea medicines. The outcome was the time to addition or switch to another antidiabetic treatment. The total
number of comorbid conditions unrelated to diabetes was identified using the pharmaceutical-based comorbidity index,
Rx-Risk-V. Competing risk regression analyses were conducted, with adjustments for a number of covariates that included
age, gender, residential status, use of endocrinology service, number of hospitalisation episodes and adherence to diabetes
medicines. Overall, 20134 veterans were included in the study. At one year, 23.5% of patients with diabetes had a second
medicine added or had switched to another medicine, with 41.4% progressing by 4 years. The number of unrelated
comorbidities was significantly associated with the time to addition of an antidiabetic medicine or switch to insulin
(subhazard ratio [SHR] 0.87 [95% CI 0.84–0.91], P,0.001). Depression, cancer, chronic obstructive pulmonary disease,
dementia, and Parkinson’s disease were individually associated with a decreased likelihood of therapeutic progression. Age,
residential status, number of hospitalisations and adherence to anti-diabetic medicines delayed therapeutic progression.
Conclusions/Significance: Increasing numbers of unrelated conditions decreased the likelihood of therapeutic progression
in veterans with diabetes. These results have implications for the development of quality measures, clinical guidelines and
the construction of models of care for management of diabetes in elderly people with comorbidities.
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Introduction
Several studies have shown that glycemic control remains
suboptimal in many patients with diabetes [1,2,3,4,5]. Progressive
decline of b-cell function and consequent deterioration of glycemic
control means that most patients eventually require treatment
intensification with increased doses and/or the addition of other
antidiabetic medicines. In a US study, intensification of diabetes
treatment was lowest in the oldest patients and those with
additional chronic diseases [6]. Appropriate care of elderly
patients with comorbidities may involve choices that tailor
intensity of diabetes treatment to individual patient characteristics
such as life expectancy, cognitive impairment or patients’
preferences [7].
The presence of competing demands due to comorbidity may
also mean that the most pressing or symptomatic problems are
prioritised. In 2006, Piette and Kerr proposed a framework for
understanding diabetes care within the context of comorbid
chronic conditions [8]. They hypothesized that comorbid
conditions unrelated to diabetes (conditions that do not share
the same pathogenesis or management plan as diabetes) may
negatively influence the therapeutic management of diabetes. This
has been demonstrated for conditions other than diabetes. The
likelihood of treatment intensification of hypertension was shown
to decrease with increasing numbers of unrelated comorbid
conditions in US primary care practices [9]. Another study
established that the number of unrelated conditions was negatively
associated with guideline-based hyperlipidemia management in
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for cardiovascular events and cardiac death [10].
Within the population with type 2 diabetes, a small study
involving 211 patient encounters assessed the effect of additional
patient concerns on changes in antidiabetic medications [11]. No
large population studies have been undertaken in patients with
type 2 diabetes. The aim of this study was therefore to examine if
the number of comorbid conditions unrelated to type 2 diabetes
delayed therapeutic progression of diabetes treatment in Austra-
lian veterans.
Materials and Methods
Data sources and patient selection
We undertook a retrospective cohort study using the Australian
Department of Veterans’ Affairs (DVA) claims database. The
DVA claims databases contain details of all prescription
medicines, medical and allied health services and hospitalisations
subsidised by DVA. The study period was from 1 July 2000 to 30
June 2008. Veterans were included if they were eligible for all
health services subsidised by the DVA in the 12 months prior to
the date of their first (index) type 2 diabetes prescription. The
study included new users of metformin or sulfonylurea medicines
defined as those with at least two successive prescriptions of the
same medicine and no dispensings of these medicines in the 12
months prior to the index prescription. Users of other classes of
antidiabetic medicines (insulin, other oral medications, combina-
tions of metformin) were excluded as prescription of these
medicines at the initiation of diabetes treatment is uncommon in
Australia and may relate to unusual clinical circumstances [12].
Outcome definitions
Two outcomes were assessed: time to addition of a new oral
antidiabetic treatment (metformin, sulfonylura, acarbose or
thioglitazone) or switch to insulin, and time to addition of a new
antidiabetic treatment or switch to any other antidiabetic
treatment. As the database does not include information on the
prescribed dose or duration of treatment, the duration of use of
prescriptions was defined as the number of days within which 75%
of people refilled their prescriptions, as calculated from the dataset
[13].
Comorbid conditions unrelated to diabetes were identified by
using prescription dispensed data from 1 July 1999, based on
categories of the Rx-Risk-V model, a pharmaceutical-based co-
morbidity index which has been validated in the Australian
veteran population [14] (Appendix S1). Some chronic conditions
are unlikely to subside in the long term and were considered
permanently present from the first dispensing of the corresponding
prescription until the end of the follow-up. Other conditions were
considered present as long as the corresponding prescription was
dispensed. The sum of all unrelated comorbid conditions was
updated on a daily basis up to the index anti-diabetic prescription.
Seven unrelated comorbid conditions common in the elderly
population were also determined from hospital discharge diagnosis
(ICD-10) and/or ATC codes measured between the index
prescription and the outcome or study end (Table 1).
Statistical analysis
In this elderly veteran population, death is a competing risk
event which may preclude the onset of the outcome of interest,
therapeutic progression. For this reason, we calculated the
cumulative incidence of outcome of interest in the presence of
competing risk events. Competing risk regression analyses were
conducted using the Fine and Gray approach which extends the
Cox model to competing risks data by considering the sub-
distribution hazard [15]. The strength of the association between
each variable and the outcome was assessed using the sub-hazard
ratio, which is the ratio of hazards associated with the cumulative
incidence function under different values of the covariates.
Covariates included age at entry, gender, residential status
(community dwelling or age-care resident), having used an
endocrinology service, number of hospitalisation episodes (be-
tween the index diabetes prescription and therapeutic progression
or end of the study), and adherence to diabetes medicines (defined
as sufficient medicine dispensed to cover 80% to 120% of the
treatment duration). Residential status, use of an endocrinology
service and adherence were time varying and adjusted each year.
Data rendering was performed using SAS 9.1 and statistical
analyses were performed using Stata 11.0.
Results
Overall, 20134 veterans were included in the study with a mean
age of 77.3 years (SD 9.1), 64% were men, 58% were dispensed
metformin and 42% sulfonylureas. The cumulative incidences of
therapeutic progression by addition or switch to another
antidiabetic medicine are presented in Table 2 and shown in
Figures 1 and 2. At one year, 23.5% of patients with diabetes had a
second medicine added or had switched to another diabetes
medicine, 41.4% at 4 years and 51.0% at 7 years.
The results of the competing risks multivariable regression
analyses for the number of unrelated comorbidities and specific
geriatric conditions are shown in Table 3. The number of
unrelated comorbidities was significantly associated with the time
Table 1. Codes used to define specific conditions.
Diseases Selection criteria
Cancers, except non-malignant skin
cancer
ICD-10 codes: C00-C97 (excluding C44), at least one hospitalisation in the follow-up period
Chronic obstructive pulmonary
disease
ICD-10 codes: J44 or taking inhaled anticholinergic drugs (ATC code: R03BB*), at least one dispensing in the follow-up period
Dementia Dispensed anticholinesterases (ATC code: N06DA)
Depression Dispensed non-tricyclic antidepressants (ATC codes: N06AB, N06AG02, N06AX no substring), dispensings covering at least 60% of
the follow-up period
Urinary incontinence Urinary antispasmodics (ATC code GO4BD), at least one dispensing in the follow-up period
Parkinson’s disease Antiparkinson agents (ATC codes N04AA01-N04BX02, at least one dispensing in the follow-up period
doi:10.1371/journal.pone.0014024.t001
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(subhazard ratio [SHR] 0.87 [95% CI 0.84–0.91], P,0.001).
Depression, cancer, chronic obstructive pulmonary disease,
dementia, and Parkinson’s disease, were significantly associated
with a decreased likelihood of therapeutic progression. The
covariates age, residential status, number of hospitalisations and
adherence to antidiabetic medicines were all negatively associated
with therapeutic progression. The use of endocrine services
increased the likelihood of therapeutic progression
Discussion
The results of this large population based study demonstrated
that one year after initiation of diabetic therapy, 23.5% of patients
had a second medicine anti-diabetic medicine added or had
switched to another medicine. Forty-one percent progressed after
4 years. Further, increasing numbers of unrelated comorbid
conditions was found to be associated with a decreased likelihood
of therapeutic progression.
Whilst most previous studies examining therapeutic progression
have only followed patients for one year, and, in general, included
younger participants than in our study, the current results were
however similar. In a Dutch study of more than 46,000 new users
of antidiabetic medicines, the proportion of patients with an
addition or switch of antidiabetic treatment at 1 year ranged from
20.2% with a sulfonylurea initial treatment to 25.7% with
metformin initial treatment [16]. In two earlier American studies
involving 85,888 members of an American managed care
organization and 19,900 members of a pharmacy benefit
management organization, rates of therapeutic progression at 1
year were 24.5% [17] and 17.2% respectively [18]. In 4556
members of a US health care organization receiving a sulfonyl-
urea, the time to addition or switching to a second antidiabetic
medicine at 4 years ranged between 40% and 70% depending on
the level of glycated hemoglobin achieved during the first year of
treatment [19].
We confirmed our main hypothesis, that more unrelated
conditions decreased the likelihood of treatment intensification.
This result is consistent with a study involving 211 patient
encounters which showed that, among patients with a glycated
hemoglobin level greater than 7%, each additional patient concern
was associated with a 49% reduction in the likelihood of a change
in medication, independent of length of the encounter and most
recent glycated hemoglobin level [11]. The lower likelihood of
treatment intensification in elderly people with more unrelated
Figure 1. Cumulative incidence of therapeutic progression by
addition of an antidiabetic treatment or switch to insulin. The
plain line represents the cumulative incidence of therapeutic progres-
sion by addition of an antidiabetic treatment or switch to insulin. The
dash line represents the cumulative incidence of the competing risk
event, death, occurring prior to therapeutic progression.
doi:10.1371/journal.pone.0014024.g001
Figure 2. Cumulative incidence of therapeutic progression by
addition of an antidiabetic treatment or switch to any
antidiabetic medicine. The plain line represents the cumulative
incidence of therapeutic progression by addition of an antidiabetic
treatment or switch to any antidiabetic medicine. The dash line
represents the cumulative incidence of the competing risk event, death,
occurring prior to therapeutic progression.
doi:10.1371/journal.pone.0014024.g002
Table 2. Cumulative incidence of therapeutic progression.
Addition of an antidiabetic medicine or switch to
insulin
Addition of an antidiabetic medicine or switch to any
antidiabetic medicine
1 year
%
4 years
%
7 years
%
1 year
%
4 years
%s
7 years
%
Cumulative incidence of therapeutic
progression
15.3 29.0 37.4 23.5 41.4 51.0
95% CI 14.8–15.8 28.3–29.7 36.5–38.4 22.9–24.1 40.6–42.1 50.1–51.9
Cumulative incidence of death 5.2 21.7 33.9 4.3 17.7 26.9
95% CI 4.9–5.6 21.1–22.5 33.0–34.9 4.0–4.6 17.1–18.3 26.0–27.7
doi:10.1371/journal.pone.0014024.t002
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guidelines on treatment of diabetes which recommend a higher
target glycated haemoglobin may be appropriate in the elderly
population or patients with comorbidities [20]. While collectively,
unrelated comorbidity was associated with less likelihood of
treatment intensification, the presence of depression, cancer,
chronic obstructive pulmonary disease, dementia, or Parkinson’s
disease, specifically, were associated with a decreased likelihood of
treatment intensification. Patients were also less likely to have their
antidiabetic treatment intensified if they were older, adherent to
their antidiabetic medicines, living in aged care, or had been
hospitalized in the prior year. Patients were more likely to have
their antidiabetic treatment intensified if they had visited an
endocrinologist.
The DVA database does not include data on glycated
hemoglobin and we could not determine the rates of true
therapeutic failure (the inability to achieve metabolic control
when a treatment is first initiated) nor adjust for this variable in the
statistical analysis. Treatment intensification per se cannot be
taken to represent good diabetes management and it may expose
patients to increased risk of adverse effects. However, treatment
intensification has been shown to be strongly associated with
improved control of diabetes [21,22] and may represent a reliable
surrogate measure of the quality of clinical care. In addition, some
forms of treatment intensification such as increasing the dose of an
antidiabetic medicine could not be measured in the DVA data.
Piette’s framework on the impact of comorbid chronic
conditions on diabetes care is useful for understanding how
elderly people with multiple conditions are managed in clinical
practice [8]. Health professionals and patients face multiple and
sometimes conflicting challenges in deciding on the best health
care options. Intensive glycemic control may reduce risk of
diabetes microvascular complications but its effect on cardiovas-
cular outcomes is more controversial. A decision analysis showed
that, among older patients with diabetes, the presence of multiple
comorbid illnesses or functional impairments was an important
predictor of diminishing expected benefits of intensive glycemic
control [23]. These results were confirmed in a recent study that
showed that patients with high levels of comorbidity received
diminished cardiovascular benefit from intensive glycemic control
[24]. Ideally, a new multimorbidity framework is required that
would overcome the limited perspective of single disease focused
models of care, and would aid in prioritizing treatments according
to expected benefits over time, potential harms, comorbid
conditions, disabilities and patients’ preferences. It would also
seek to inform the multiple trade-offs associated with the
management of multiple comorbidities [25].
Our study was performed in the Australian veteran population.
Although the results may not be able to be generalized to the
whole elderly Australian population, the use of health services by
veterans has been shown to be similar with the rest of the
Australian community after adjustment for disability [26]. With
the current development of important healthcare reforms in
Australia, our results may inform future construction of perfor-
mance management measures for diabetes management that
includes the consideration of elderly patients with multiple
conditions.
Supporting Information
Appendix S1
Found at: doi:10.1371/journal.pone.0014024.s001 (0.05 MB
DOC)
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Table 3. Competing risk proportional hazard regression analyses of time to therapeutic progression.
Addition of an antidiabetic medicine or switch to
insulin
Addition of an antidiabetic medicine or switch to any
antidiabetic medicine
SHR 95% CI P value SHR 95% CI P value
Number of unrelated comorbidities 0.872 0.839–0.905 ,0.001 0.879 0.852–0.907 ,0.001
Cancer 0.703 0.590–0.836 ,0.001 0.690 0.605–0.788 ,0.001
Chronic obstructive pulmonary
disease
0.866 0.778–0.963 0.008 0.855 0.786–0.930 ,0.001
Dementia 0.682 0.519–0.895 0.006 0.636 0.512–0.791 ,0.001
Depression 0.803 0.742–0.868 ,0.001 0.781 0.734–0.832 ,0.001
Urinary incontinence 0.794 0.542–1.164 0.237 0.752 0.555–1.02 0.067
Parkinson’s disease 0.565 0.457–0.698 ,0.001 0.635 0.544–0.742 ,0.001
Age 0.975 0.972–0.977 ,0.001 0.981 0.978–0.983 ,0.001
Number of hospitalisations 0.776 0.744–0.809 ,0.001 0.811 0.788–0.834 ,0.001
Adherence to antidiabetic medicines0.599 0.556–0.644 ,0.001 0.545 0.513–0.579 ,0.001
Residency (aged care versus
community)
0.892 0.853–0.934 ,0.001 0.884 0.849–0.920 ,0.001
Endocrinology service 1.196 1.145–1.250 ,0.001 1.317 1.269–1.367 ,0.001
SHR, Subdistribution Hazard Ratio from multivariable competing risk regression analyses.
doi:10.1371/journal.pone.0014024.t003
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